{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:49:21Z","timestamp":1787870961146,"version":"build-2784847793"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1327,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600187"],"award-info":[{"award-number":["81600187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800891"],"award-info":[{"award-number":["81800891"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600187"],"award-info":[{"award-number":["81600187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800891"],"award-info":[{"award-number":["81800891"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Radiofrequency catheter ablation (RFCA) is now an established therapeutic option for patients with atrial fibrillation (AF), but the long-term recurrence rate of AF is still high. Sacubitril\/valsartan (Sac\/Val) is superior to valsartan in attenuating ventricular remodelling and improving clinical outcomes in heart failure patients, but whether this additional benefit exists in reversing atrial remodelling and reducing AF recurrence of RFCA-treated AF patients remains uncovered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients that had undergone RFCA were enrolled and randomly assigned 1:1 to valsartan (160 mg\/day) or Sac\/Val (200 mg\/day) treatment group, in addition to other standard treatment of AF. Patients were followed up for 24 weeks. Echocardiography and ambulatory Holter monitoring for 24 h was performed at 24 weeks after RFCA. The primary end point was the change of atrial diameter from baseline to 24 weeks after RFCA. Second end points included the recurrence rate of AF, all-cause hospitalization and all-cause death. A total of 64 AF patients were enrolled, 32 of which received Sac\/Val and 32 received valsartan treatment. There was no difference in the age (64.8 \u00b1 9.8 vs. 63.7 \u00b1 9.0, P = 0.634), gender (per cent of male: 59.4% vs. 50.0%, P = 0.616), heart rate (84.7 \u00b1 4.1 b.p.m. vs. 80.9 \u00b1 2.6 b.p.m., P = 0.428), systolic (127.5 \u00b1 15.4 mmHg vs. 130.0 \u00b1 17.8 mmHg, P = 0.549) or diastolic (81.7 \u00b1 9.8 mmHg vs. 79.9 \u00b1 12.6, P = 0.537) blood pressure upon admission between valsartan and Sac\/Val treatment groups. The percentage of persistent AF was also comparable (43.8% vs. 53.1%, P = 0.617) in both treatment groups. Patients receiving Sac\/Val treatment displayed significant decrease in the left atrial diameter (4.3 \u00b1 0.5 cm to 3.8 \u00b1 0.5 cm, P &amp;lt; 0.001), volume index (48.0 \u00b1 6.4 mL\/m2 to 41.7 \u00b1 7.0 mL\/m2, P &amp;lt; 0.001), and right atrial diameter (4.4 \u00b1 0.8 cm to 3.9 \u00b1 0.7 cm, P = 0.017) from baseline to 24 weeks after RFCA. This effect was not observed in valsartan treatment group. There was a numerical decrease in AF recurrence rate in the Sac\/Val group compared with valsartan group (9.4% vs. 15.6%), although this difference did not reach a statistical significance (P = 0.708). No difference in all-cause hospitalization rate (6.3% in each group) or all-cause death rate (0% in each group) was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data indicate that Sac\/Val is superior to valsartan in attenuating atrial structural remodelling in catheter ablation-treated AF patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13937","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:54:07Z","timestamp":1650329647000},"page":"2428-2434","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Sacubitril\/Valsartan Attenuates Atrial Structural Remodelling in Atrial Fibrillation Patients"],"prefix":"10.1093","volume":"9","author":[{"given":"Liu","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]},{"name":"Department of Cardiology, The First Affiliated Hospital of Nanchang University , Nanchang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiheng","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"2026012114150283200_ehf213937-bib-0001","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"2026012114150283200_ehf213937-bib-0002","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3892\/etm.2015.2545","article-title":"Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: A meta-analysis of randomized controlled trials","volume":"10","author":"Shi","year":"2015","journal-title":"Exp Ther Med"},{"key":"2026012114150283200_ehf213937-bib-0003","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.005250","article-title":"Ten-year clinical outcome after circumferential pulmonary vein isolation utilizing the Hamburg approach in patients with symptomatic drug-refractory paroxysmal atrial fibrillation","volume":"11","author":"Tilz","year":"2018","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026012114150283200_ehf213937-bib-0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2007.09.026","article-title":"Structural and functional remodeling of the left atrium: Clinical and therapeutic implications for atrial fibrillation","volume":"51","author":"Casaclang-Verzosa","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026012114150283200_ehf213937-bib-0005","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/ehjci\/jet017","article-title":"Left atrial volumetry from routine diagnostic work up prior to pulmonary vein ablation is a good predictor of freedom from atrial fibrillation","volume":"14","author":"Sohns","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114150283200_ehf213937-bib-0006","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/eurheartj\/ehm027","article-title":"Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation","volume":"28","author":"Berruezo","year":"2007","journal-title":"Eur Heart J"},{"key":"2026012114150283200_ehf213937-bib-0007","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/europace\/eur364","article-title":"Association between left atrial size and atrial fibrillation recurrence after single circumferential pulmonary vein isolation: A systematic review and meta-analysis of observational studies","volume":"14","author":"Zhuang","year":"2012","journal-title":"Europace"},{"key":"2026012114150283200_ehf213937-bib-0008","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/13543784.2013.797963","article-title":"The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure","volume":"22","author":"Voors","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"2026012114150283200_ehf213937-bib-0009","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","article-title":"Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: Rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026012114150283200_ehf213937-bib-0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114150283200_ehf213937-bib-0011","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114150283200_ehf213937-bib-0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173120","article-title":"Sacubitril\/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation","volume":"881","author":"Li","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2026012114150283200_ehf213937-bib-0013","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy","volume":"8","author":"von Lueder","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026012114150283200_ehf213937-bib-0014","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.jacc.2018.07.102","article-title":"Sacubitril\/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits","volume":"72","author":"Torrado","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114150283200_ehf213937-bib-0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01285","article-title":"Sacubitril\/valsartan improves left atrial and left atrial appendage function in patients with atrial fibrillation and in pressure overload-induced mice","volume":"10","author":"Suo","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026012114150283200_ehf213937-bib-0016","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012114150283200_ehf213937-bib-0017","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: A report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012114150283200_ehf213937-bib-0018","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/europace\/eur023","article-title":"Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: Secondary prevention","volume":"13","author":"Savelieva","year":"2011","journal-title":"Europace"},{"key":"2026012114150283200_ehf213937-bib-0019","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eur002","article-title":"Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: Primary prevention","volume":"13","author":"Savelieva","year":"2011","journal-title":"Europace"},{"key":"2026012114150283200_ehf213937-bib-0020","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","article-title":"Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis","volume":"45","author":"Healey","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026012114150283200_ehf213937-bib-0021","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0735-1097(03)00464-9","article-title":"Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation","volume":"41","author":"Kumagai","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026012114150283200_ehf213937-bib-0022","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jacc.2008.08.071","article-title":"Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients","volume":"53","author":"Belluzzi","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026012114150283200_ehf213937-bib-0023","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/01.CIR.0000022665.18619.83","article-title":"Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study","volume":"106","author":"Madrid","year":"2002","journal-title":"Circulation"},{"key":"2026012114150283200_ehf213937-bib-0024","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa0805710","article-title":"Valsartan for prevention of recurrent atrial fibrillation","volume":"360","author":"GISSI-AF Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012114150283200_ehf213937-bib-0025","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/CIRCIMAGING.111.965954","article-title":"Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: The GISSI-AF echocardiographic substudy","volume":"4","author":"Staszewsky","year":"2011","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012114150283200_ehf213937-bib-0026","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: The results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114150283200_ehf213937-bib-0027","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of Sacubitril-valsartan vs Enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: A randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"2026012114150283200_ehf213937-bib-0028","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12265-021-10137-5","article-title":"Sacubitril\/valsartan decreases atrial fibrillation susceptibility by inhibiting angiotensin II-induced atrial fibrosis through p-Smad2\/3, p-JNK, and p-p38 signaling pathways","volume":"15","author":"Li","year":"2022","journal-title":"J Cardiovasc Transl Res"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13937","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13937","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/4\/2428\/65349316\/eschf_9_4_2428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/4\/2428\/65349316\/eschf_9_4_2428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:17:56Z","timestamp":1769023076000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/4\/2428\/8322978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,18]]},"published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13937","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8]]},"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"2021-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}